MDK and breast cancer: NR3C1 is a potential downstream target of the NF-κB pathway, and silencing MDK (Midkine) by suppressing NF-κB activation and nuclear distribution reduces NR3C1 expression, thereby significantly inhibiting BC cell proliferation and migration (Zhang et al., 2022).